-
The CRO sector continues to rise! Kailai Ying rose to the limit, and many stocks rose more than 8
Time of Update: 2023-02-01
【Pharmaceutical Network Pharmaceutical Stock Market】On January 16, the CRO sector continued to rise, as of 14:35 on the 16th, Kailaiying's A shares rose to the limit, H shares once rose by more than 15%, Viva Biologics rose by more than 14%, WuXi AppTec rose by more than 8%, and Zhaoyan New Drug rose by more than 5%.
-
Bristol-Myers Squibb relatlimab for the treatment of melanoma
Time of Update: 2022-10-03
Immune checkpoint inhibitors are a class of cancer immunotherapies that have been approved for 8 drugs, 7 of which have a mechanism similar to the PD-1 inhibitors sintilimab (Xindilizumab) of Eli Lilly and Cinda Biologics, which have been marketed in China under the brand name Tyvyt (Dabosu).
-
The supply of protective masks is in short supply, but the United States refuses to use Chinese KN95 masks
Time of Update: 2022-08-22
KN95 masks from China are considered to be an alternative to N95 masks, but the FDA has refused to import Chinese KN95 masks According to foreign media buzzfeednews reporters, the United States is currently facing a shortage of N95 masks.
-
Pharmacies have become a new trend in collecting and purchasing, and a large number of drugs will be reduced in price
Time of Update: 2022-02-19
Recently, the Henan Medical Insurance Bureau issued the "Notice on the Results of the Selected Results of the Centralized and Volume Purchase of Relevant Drug Retail Chain Enterprises" (hereinafter referred to as the "Notice") .
-
Russia's wild Pacific salmon fishing season officially begins
Time of Update: 2021-06-16
The Russian Pacific Fisheries Research Center (RINRO) expects this year’s catch to increase by 35% compared to last year, with a total catch of 459,300 tons .
-
Mitsubishi Tanabe Pharmaceutical's CD19 monoclonal antibody Uplizna approved in Japan
Time of Update: 2021-04-24
Mitsubishi Tanabe Pharmaceutical Company (MTPC) recently announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the anti-CD19 monoclonal antibody Uplizna (MEDI-551, generic name: inebilizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD, optic nerve spinal cord) Inflammation) patients to prevent the recurrence of the disease.
-
2020 Oncology New Drug Data Card-Inituzumab
Time of Update: 2021-03-24
The data show that initumumab combined with vinorelbine In the treatment of HER2-positive metastatic breast cancer patients who have received one or more chemotherapy regimens in the past, compared with vinorelbine can significantly prolong the median PFS of the primary endpoint (39.
-
The pharmaceutical industry ushered in the 3.0 era four main coils set 12 stocks
Time of Update: 2021-02-17
Yesterday, the Shanghai and Shenzhen markets showed a general pattern of growth, the major indices opened high, the center of gravity all the way, on the surface, pharmaceutical stocks have been active, as of the close, the overall rise of the sector exceeded 2%.
-
The patient raged behind the hospital: there were medicines on the catalogue and the hospital was out of stock
Time of Update: 2021-02-01
Whether the former people can save money can be realized depends on hospital doctors, pharmaceutical companies, medical insurance, commercial insurance, a number of factors to participate in their own just bear, the latter health insurance is the ability to make independent decisions, through DRG, DIP, and drug proportion and so on to assess.
-
Fuhong Hanjun Adamu single anti-new adaptive disorder was approved
Time of Update: 2021-01-23
Comprehensive Drug Database (PDB) as of December 2020, Fuhong Hanxuan has invested approximately 270 million yuan in research and development of the new drug, including approved market-listed and staphylactics.
-
The announcement of the State Drug Administration on the construction of a traceability system for key varieties of information technology
Time of Update: 2020-11-02
(2) Drug market license holders and pharmaceutical business enterprises shall establish and implement drug traceability systems in accordance with the standards and normative requirements of the Regulations on the Retrospective Construction of Drug Informationization, provide retrospective information and ensure the traceability of drugs.
-
The National Health Insurance Agency has issued a message to these varieties of opportunities
Time of Update: 2020-08-26
Take Miao Health as an example, for the combination of pharmaceutical companies and commercial insurance landing there are two service options: the first is relying on Miao health health management capabilities, data as a grasping hand, the integration of pharmaceutical, insurance resources, to create a "drug and services and insurance" integrated product solutions.
-
Girls must know the skin care ingredients list, in order not to fool buy a bunch of three no products, you have to learn to look at the ingredients first
Time of Update: 2020-08-18
original title: girls must know the skin care ingredients table, in order not to buy a bunch of three no products, you have to learn to look at ingredients first!
-
The market lost $6 billion overnight! Beida is questioned again, the daily rise is "the penultimate
Time of Update: 2020-07-28
Guide: The stock market fell due to the delay in reply to the Shenzhen Stock Exchange inquiry the opening price of The Day Beida Pharmaceuticals continued to fall as of the morning point formally stop
-
NBE . . . Independent innovation: Huang Bo/Wang Ximo developed a new technology for the treatment of vesicle bile duct cancer
Time of Update: 2020-07-18
on July 6, 2020, Huang Bo team of Institute of basic medicine, Chinese Academy of Medical Sciences and Wang Ximo's team from Tianjin Nankai Hospital Affiliated to Nankai University published in the journal Nature biomedical engineering the title "methotrexate loaded tumor cell derived microorganisms can relieve biliary obstruction in patients with external choledochocarcinoma This study not only demonstrated the efficacy and safety of drug loaded vesicle therapy for patients with cholangiocarcinoma, but also clarified its therapeutic mechanism.
